Sitafloxacin resistance in Helicobacter pylori isolates and sitafloxacin-based triple therapy as a third-line regimen in Japan

International Journal of Antimicrobial Agents

Volumn 39, Issue 4, 2012, Pages 352-355

  Hirata, Yoshihiro ^a   Ohmae, Tomoya ^b   Yanai, Ayako ^c   Sakitani, Kosuke ^a   Hayakawa, Yoku ^a   Yoshida, Shuntaro ^a   Sugimoto, Takafumi ^a   Mitsuno, Yuzo ^d   Akanuma, Masao ^c   Yamaji, Yutaka ^a   Ogura, Keiji ^e   Maeda, Shin ^f   Koike, Kazuhiko ^a  

^a UNIVERSITY OF TOKYO   (Japan)

^b JR Tokyo General Hospital   (Japan)

^c INSTITUTE FOR ADULT DISEASES   (Japan)

^d JAPANESE RED CROSS MEDICAL CENTER   (Japan)

^e TOKYO METROPOLITAN POLICE HOSPITAL   (Japan)

^f YOKOHAMA CITY UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

Drug regimen; Drug resistance; Helicobacter pylori

Indexed keywords

AMOXICILLIN; LEVOFLOXACIN; RABEPRAZOLE; SITAFLOXACIN;

ADULT; ANTIBIOTIC SENSITIVITY; ARTICLE; BACTERIUM ISOLATE; BACTERIUM MUTANT; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG EFFICACY; DRUG SAFETY; ERADICATION THERAPY; FEMALE; HELICOBACTER INFECTION; HUMAN; JAPAN; MALE; MINIMUM INHIBITORY CONCENTRATION; MULTICENTER STUDY; NONHUMAN; PH; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; TREATMENT OUTCOME;

AMOXICILLIN; ANTI-BACTERIAL AGENTS; DISEASE ERADICATION; DNA GYRASE; DRUG RESISTANCE, BACTERIAL; FEMALE; FLUOROQUINOLONES; GENES, BACTERIAL; HELICOBACTER INFECTIONS; HELICOBACTER PYLORI; HUMANS; HYDROGEN-ION CONCENTRATION; INHIBITORY CONCENTRATION 50; JAPAN; MALE; MICROBIAL SENSITIVITY TESTS; MIDDLE AGED; MUTATION; PEPSINOGEN A; PEPSINOGEN C; PROSPECTIVE STUDIES;

EID: 84858283631     PISSN: 09248579     EISSN: 18727913     Source Type: Journal    
DOI: 10.1016/j.ijantimicag.2011.12.002     Document Type: Article

References (15)

1. Suerbaum S, Michetti P. Helicobacter pylori infection. N Engl J Med 2002;347:1175-86.
2. Asaka M, Kato M, Takahashi S, Fukuda Y, Sugiyama T, Ota H, et al. Guidelines for the management of Helicobacter pylori infection in Japan: 2009 revised edition. Helicobacter 2010;15:1-20.
3. Cianci R, Montalto M, Pandolfi F, Gasbarrini GB, Cammarota G. Third-line rescue therapy for Helicobacter pylori infection. World J Gastroenterol 2006;12:2313-9.
4. Nishizawa T, Suzuki H, Hibi T. Quinolone-based third-line therapy for Helicobacter pylori eradication. J Clin Biochem Nutr 2009;44:119-24.
5. O'Connor A, Gisbert J, O'Morain C. Treatment of Helicobacter pylori infection. Helicobacter 2009;14(Suppl. 1):46-51.
6. Gisbert JP, Morena F. Systematic review and meta-analysis: levofloxacin-based rescue regimens after Helicobacter pylori treatment failure. Aliment Pharmacol Ther 2006;23:35-44. (Pubitemid 43381164)
7. Tankovic J, Lascols C, Sculo Q, Petit JC, Soussy CJ. Single and double mutations in gyrA but not in gyrB are associated with low- and high-level fluoroquinolone resistance in Helicobacter pylori. Antimicrob Agents Chemother 2003;47:3942-4. (Pubitemid 37485011)
8. Perna F, Zullo A, Ricci C, Hassan C, Morini S, Vaira D. Levofloxacin-based triple therapy for Helicobacter pylori re-treatment: role of bacterial resistance. Dig Liver Dis 2007;39:1001-5. (Pubitemid 350018698)
9. Sánchez JE, Sáenz NG, Rincón MR, Martín IT, Sánchez EG, Martínez MJ. Susceptibility of Helicobacter pylori to mupirocin, oxazolidinones, quinupristin/dalfopristin and new quinolones. J Antimicrob Chemother 2000;46:283-5. (Pubitemid 30639300)
10. Suzuki H, Nishizawa T, Muraoka H, Hibi T. Sitafloxacin and garenoxacin may overcome the antibiotic resistance of Helicobacter pylori with gyrA mutation. Antimicrob Agents Chemother 2009;53:1720-1.
11. Murakami K, Okimoto T, Kodama M, Tanahashi J, Fujioka T, Ikeda F, et al. Sitafloxacin activity against Helicobacter pylori isolates, including those with gyrA mutations. Antimicrob Agents Chemother 2009;53:3097-9.
12. Kim JM, Kim JS, Kim N, Jung HC, Song IS. Distribution of fluoroquinolone MICs in Helicobacter pylori strains from Korean patients. J Antimicrob Chemother 2005;56:965-7. (Pubitemid 41631929)
13. Cattoir V, Nectoux J, Lascols C, Deforges L, Delchier JC, Megraud F, et al. Update on fluoroquinolone resistance in Helicobacter pylori: new mutations leading to resistance and first description of a gyrA polymorphism associated with hypersusceptibility. Int J Antimicrob Agents 2007;29:389-96. (Pubitemid 46357606)
14. Matsumoto Y, Miki I, Aoyama N, Shirasaka D, Watanabe Y, Morita Y, et al. Levofloxacin- versus metronidazole-based rescue therapy for H. pylori infection in Japan. Dig Liver Dis 2005;37:821-5. (Pubitemid 44356109)
15. El-Omar EM, Oien K, El-Nujumi A, Gillen D, Wirz A, Dahill S, et al. Helicobacter pylori infection and chronic gastric acid hyposecretion. Gastroenterology 1997;113:15-24. (Pubitemid 27281753)